October 17, 2022 – Cambridge Isotope Laboratories, Inc. Embarks on Largest Expansion Project in the Company's History
TEWKSBURY, Mass., October 17, 2022 - Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (13C), has embarked on the largest expansion in the company's history. This strategic undertaking, which has been aptly named North Star, will significantly increase 13C production by building a separate cryogenic distillation facility for carbon monoxide.
September 26, 2022 – Cambridge Isotope Laboratories, Inc. (CIL) Partners With ISOtopic Solutions to Release the New Stable Isotope-Labeled and Unlabeled Crude Lipid Yeast Extracts
Cambridge Isotope Laboratories, Inc. (CIL) has partnered with ISOtopic Solutions to release the new stable isotope-labeled and unlabeled Crude Lipid Yeast Extracts. These are designed to render 100s of fatty acids and lipids for use in MS lipidomics research and development.
August 11, 2022 – CIL Announces New Hire John Bakke as Vice President of Finance
Cambridge Isotope Laboratories, Inc, the world’s leading manufacturer of stable isotopes and stable isotope-labeled compounds, is pleased to announce the addition of John Bakke as Vice President of Finance. John reports directly to the CEO, Cliff Caldwell.
March 31, 2022 – Otsuka Subsidiary to Receive Payment and Royalties from US Approval of Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer
Otsuka Pharmaceutical Co., Ltd (Otsuka) is pleased to announce that ABX advanced biochemical compounds GmbH (ABX), a subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), which in turn is a wholly owned subsidiary of Otsuka, expects to receive payments and royalties from Endocyte Inc., a Novartis company, based on the US FDA regulatory approval of Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan), formerly referred to as 177Lu-PSMA-617, a radioligand therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.
February 7, 2022 – Cambridge Isotope Laboratories, Inc. (CIL) Hires Ashley Schultz as New Regional Sales Manager
Cambridge Isotope Laboratories, Inc. (CIL) is pleased to announce the hire of Ashley Schultz as a new Regional Sales Manager. Schultz will lead sales for CIL in the Mid-Atlantic and Southeast regions, covering Pennsylvania, Delaware, Maryland, West Virginia, Virginia, Kentucky, Tennessee, North Carolina, South Carolina, Alabama, Georgia, and Florida.